These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Bhattacharyya B; Panda D; Gupta S; Banerjee M Med Res Rev; 2008 Jan; 28(1):155-83. PubMed ID: 17464966 [TBL] [Abstract][Full Text] [Related]
29. New ligands of the tubulin colchicine site based on X-ray structures. Álvarez R; Medarde M; Peláez R Curr Top Med Chem; 2014; 14(20):2231-52. PubMed ID: 25434358 [TBL] [Abstract][Full Text] [Related]
30. New indole-based chalconoids as tubulin-targeting antiproliferative agents. Mirzaei H; Shokrzadeh M; Modanloo M; Ziar A; Riazi GH; Emami S Bioorg Chem; 2017 Dec; 75():86-98. PubMed ID: 28922629 [TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of noscapine analogues as microtubule-interfering agents. Dai HL; Zheng JB; Lin M; Zheng J; Zhou FS; Dong XC; Guo L; Liu JW; Wen R Yao Xue Xue Bao; 2012 Oct; 47(10):1347-57. PubMed ID: 23289148 [TBL] [Abstract][Full Text] [Related]
32. Biochemical characterization and molecular dynamic simulation of β-sitosterol as a tubulin-binding anticancer agent. Mahaddalkar T; Suri C; Naik PK; Lopus M Eur J Pharmacol; 2015 Aug; 760():154-62. PubMed ID: 25912799 [TBL] [Abstract][Full Text] [Related]
33. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity. Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884 [TBL] [Abstract][Full Text] [Related]
34. 4(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin. Lin MS; Hong TM; Chou TH; Yang SC; Chung WC; Weng CW; Tsai ML; Cheng TR; Chen JJW; Lee TC; Wong CH; Chein RJ; Yang PC Eur J Med Chem; 2019 Nov; 181():111584. PubMed ID: 31419740 [TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of a novel tubulin inhibitor SKLB0565 targeting the colchicine binding site. Hu X; Li L; Zhang Q; Wang Q; Feng Z; Xu Y; Xia Y; Yu L Bioorg Chem; 2020 Apr; 97():103695. PubMed ID: 32120073 [TBL] [Abstract][Full Text] [Related]
36. Quinolin-6-Yloxyacetamides Are Microtubule Destabilizing Agents That Bind to the Colchicine Site of Tubulin. Sharma A; Sáez-Calvo G; Olieric N; de Asís Balaguer F; Barasoain I; Lamberth C; Díaz JF; Steinmetz MO Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640209 [TBL] [Abstract][Full Text] [Related]
37. 9-PAN promotes tubulin- and ROS-mediated cell death in human triple-negative breast cancer cells. Verma P; Nagireddy PKR; Prassanawar SS; Nirmala JG; Gupta A; Kantevari S; Lopus M J Pharm Pharmacol; 2020 Nov; 72(11):1585-1594. PubMed ID: 32959391 [TBL] [Abstract][Full Text] [Related]
38. Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents. Duan Y; Liu W; Tian L; Mao Y; Song C Curr Top Med Chem; 2019; 19(15):1289-1304. PubMed ID: 31210108 [TBL] [Abstract][Full Text] [Related]
39. Discovery of noscapine derivatives as potential β-tubulin inhibitors. Nemati F; Salehi P; Bararjanian M; Hadian N; Mohebbi M; Lauro G; Ruggiero D; Terracciano S; Bifulco G; Bruno I Bioorg Med Chem Lett; 2020 Oct; 30(20):127489. PubMed ID: 32784088 [TBL] [Abstract][Full Text] [Related]
40. 9-Arylimino noscapinoids as potent tubulin binding anticancer agent: chemical synthesis and cellular evaluation against breast tumour cells. Patel AK; Meher RK; Nagireddy PK; Pragyandipta P; Pedapati RK; Kantevari S; Naik PK SAR QSAR Environ Res; 2021 Apr; 32(4):269-291. PubMed ID: 33687299 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]